Anti-LYPD6 monoclonal antibody

Anti-LYPD6 antibody for FACS & in-vivo assay

Target products collectionGo to LYPD6/LYPD6 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP2550-Ab-1/ GM-Tg-hg-MP2550-Ab-2Anti-Human LYPD6 monoclonal antibodyHuman
GM-Tg-rg-MP2550-Ab-1/ GM-Tg-rg-MP2550-Ab-2Anti-Rat LYPD6 monoclonal antibodyRat
GM-Tg-mg-MP2550-Ab-1/ GM-Tg-mg-MP2550-Ab-2Anti-Mouse LYPD6 monoclonal antibodyMouse
GM-Tg-cynog-MP2550-Ab-1/ GM-Tg-cynog-MP2550-Ab-2Anti-Cynomolgus/ Rhesus macaque LYPD6 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP2550-Ab-1/ GM-Tg-felg-MP2550-Ab-2Anti-Feline LYPD6 monoclonal antibodyFeline
GM-Tg-cang-MP2550-Ab-1/ GM-Tg-cang-MP2550-Ab-2Anti-Canine LYPD6 monoclonal antibodyCanine
GM-Tg-bovg-MP2550-Ab-1/ GM-Tg-bovg-MP2550-Ab-2Anti-Bovine LYPD6 monoclonal antibodyBovine
GM-Tg-equg-MP2550-Ab-1/ GM-Tg-equg-MP2550-Ab-2Anti-Equine LYPD6 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP2550-Ab-1/ GM-Tg-hg-MP2550-Ab-2; GM-Tg-rg-MP2550-Ab-1/ GM-Tg-rg-MP2550-Ab-2;
GM-Tg-mg-MP2550-Ab-1/ GM-Tg-mg-MP2550-Ab-2; GM-Tg-cynog-MP2550-Ab-1/ GM-Tg-cynog-MP2550-Ab-2;
GM-Tg-felg-MP2550-Ab-1/ GM-Tg-felg-MP2550-Ab-2; GM-Tg-cang-MP2550-Ab-1/ GM-Tg-cang-MP2550-Ab-2;
GM-Tg-bovg-MP2550-Ab-1/ GM-Tg-bovg-MP2550-Ab-2; GM-Tg-equg-MP2550-Ab-1/ GM-Tg-equg-MP2550-Ab-2
Products NameAnti-LYPD6 monoclonal antibody
Formatmab
Target NameLYPD6
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-LYPD6 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species LYPD6 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP2550
    Target NameLYPD6
    Gene ID130574,320343,679564,693649,608509,101099391,100337491,100056595
    Gene Symbol and SynonymsE130115E03Rik,LYPD6
    Uniprot AccessionQ86Y78,D3ZTT2
    Uniprot Entry NameLYPD6_HUMAN,LYPD6_RAT
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000187123
    Target ClassificationN/A

    The target: LYPD6, gene name: LYPD6, also named as . Members of the LY6 protein family (see SLURP1; MIM 606119), such as LYPD6, have at least one 80-amino acid LU domain that contains 10 conserved cysteines with a defined disulfide-bonding pattern (Zhang et al., 2010 [PubMed 19653121]).[supplied by OMIM, Apr 2010].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.